Phreesia (NYSE:PHR) Posts Earnings Results, Misses Estimates By $0.06 EPS

Phreesia (NYSE:PHR) issued its quarterly earnings results on Wednesday. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.06), FiscalAI reports. The company had revenue of $129.46 million during the quarter, compared to analyst estimates of $129.06 million. Phreesia had a net margin of 1.85% and a return on equity of 5.13%.

Phreesia Price Performance

Shares of PHR traded up $0.04 during mid-day trading on Wednesday, hitting $11.88. The company’s stock had a trading volume of 496,678 shares, compared to its average volume of 1,497,535. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.41. Phreesia has a 1-year low of $7.77 and a 1-year high of $31.83. The firm has a market capitalization of $734.33 million, a P/E ratio of 79.20 and a beta of 0.85. The firm has a 50-day simple moving average of $11.14 and a 200 day simple moving average of $10.48.

Institutional Investors Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently bought and sold shares of PHR. Van ECK Associates Corp grew its position in shares of Phreesia by 78.7% in the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock valued at $42,000 after purchasing an additional 1,102 shares during the last quarter. State of Wyoming acquired a new stake in Phreesia during the 4th quarter valued at $99,000. Tower Research Capital LLC TRC grew its holdings in Phreesia by 332.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,610 shares of the company’s stock valued at $160,000 after buying an additional 4,313 shares during the last quarter. State of Tennessee Department of Treasury purchased a new position in Phreesia during the fourth quarter worth $202,000. Finally, Creative Planning purchased a new position in Phreesia during the third quarter worth $218,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Truist Financial increased their price objective on Phreesia from $11.00 to $12.00 and gave the stock a “hold” rating in a research report on Thursday, May 28th. Wells Fargo & Company restated an “equal weight” rating and set a $9.00 price target (down from $15.00) on shares of Phreesia in a research note on Wednesday, May 20th. Wall Street Zen upgraded shares of Phreesia from a “hold” rating to a “buy” rating in a research report on Saturday, May 30th. Piper Sandler cut shares of Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 price objective on the stock. in a research note on Thursday, May 28th. Finally, Weiss Ratings upgraded shares of Phreesia from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, July 20th. Nine analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $16.65.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.